Literature DB >> 11967626

Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.

Tomohisa Mori1, Mutsuko Nomura, Hiroshi Nagase, Minoru Narita, Tsutomu Suzuki.   

Abstract

RATIONALE: We previously demonstrated that the prototypical kappa-opioid receptor agonist U-50,488H did not affect the discriminative stimulus effects of cocaine, and the dose of U-50,488H which significantly induced aversive effects attenuated the rewarding effects of cocaine.
OBJECTIVES: In the present study, the effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine were examined in rats.
METHODS: In the drug discrimination procedure, the effects of TRK-820 on the discriminative stimulus effects of cocaine were examined in rats that had been trained to discriminate between 10 mg/kg cocaine and saline. TRK-820-induced place preference or place aversion and the effects of TRK-820 on the cocaine (4 mg/kg)-induced place preference were examined using a conditioned place preference procedure in rats.
RESULTS: TRK-820 did not engender cocaine-like responding in rats trained to discriminate between 10 mg/kg cocaine and saline. In combination tests, low doses of TRK-820, which did not affect the response rate, significantly attenuated the discriminative stimulus effects of cocaine, and these effects of TRK-820 were reversed by a kappa-opioid receptor antagonist, nor-BNI. In the conditioned place preference procedure, low doses of TRK-820, which did not affect the response rate in the drug discrimination, did not produce either place preference or place aversion, whereas, higher dose (80 microg/kg) of TRK-820 slightly but significantly induced a place aversion. Under these conditions, the cocaine-induced place preference was completely attenuated by low doses of TRK-820. These results may prompt further investigation of the effectiveness of the new kappa-opioid receptor agonist TRK-820 as a novel pharmacotherapeutic compound for the treatment of cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967626     DOI: 10.1007/s00213-002-1028-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Authors:  Mark A Smith; Keith A Gordon; Christopher K Craig; Paul A Bryant; M Eric Ferguson; Adam M French; Jason D Gray; Jacob M McClean; Jonathan C Tetirick
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

2.  Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area.

Authors:  A P Piras; Y Zhou; S D Schlussman; A Ho; M J Kreek
Journal:  Neuroscience       Date:  2010-05-07       Impact factor: 3.590

3.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

4.  Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.

Authors:  Selena S Schattauer; Jamie R Kuhar; Allisa Song; Charles Chavkin
Journal:  Cell Signal       Date:  2017-01-11       Impact factor: 4.315

Review 5.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 6.  The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse.

Authors:  Sunmee Wee; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

Review 7.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

8.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats.

Authors:  E Andrew Townsend; Jennifer E Naylor; S Stevens Negus; Shelley R Edwards; Hina N Qureshi; Hunter W McLendon; Christopher R McCurdy; Coco N Kapanda; Jussara M do Carmo; Fernanda S da Silva; John E Hall; Kenneth J Sufka; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.